Loading
AMEXHealthcareBiotechnology
Latest quote
$1.31
−$0.05 · -3.68%
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Latest quote
$1.31
−$0.05 · -3.68%
After-hours
$1.27
−$0.04 · -3.05%
Sep 10, 5:46 PM ET
Regular session · ET · Market data may be delayed.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Day range
Current $1.31
52-week range
Current $1.31
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
48
Mixed
Risk
74
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Day range
Current $1.31
52-week range
Current $1.31
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 45K USD | 449K USD |
| Cost of goods sold | 1.65M USD | — | 1.26M USD | 274K USD | 94K USD |
| Gross profit | −1.65M USD | — | −1.26M USD | −229K USD | 355K USD |
| Research and development | 9.74M USD | 8.88M USD | 13.01M USD | 7.26M USD | 4.67M USD |
| Selling, general, and administrative | 10.5M USD | 12.9M USD | 15.98M USD | 15.64M USD | 6.16M USD |
| Operating expenses | 18.59M USD | 21.78M USD | 27.74M USD | 22.9M USD | 10.84M USD |
| Interest expense | 207K USD | 933K USD | 3.75M USD | 158K USD | 614K USD |
| Depreciation and amortization | 1.65M USD | 1.54M USD | 1.26M USD | 260K USD | 156K USD |
| Operating income | −20.24M USD | −21.78M USD | −28.99M USD | −23.13M USD | −10.48M USD |
| Net income | −19.91M USD | −22.14M USD | −29.22M USD | −25.43M USD | −10.93M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.50
319.85% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 31, 2026 | 1:16 | — | — |
Stock split | Aug 5, 2025 | 1:12 | — | — |
Stock split | Jul 15, 2024 | 1:10 | — | — |
Effective Jul 31, 2026
1:16
Effective Aug 5, 2025
1:12
Effective Jul 15, 2024
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
